• Phosbind Biotin LC: Technical Guide for Phosphorylated Prote

  2026-04-25

  Phosbind Biotin LC provides sequence-independent detection of phosphorylated proteins on PVDF membranes during Western Blot workflows, overcoming the limitations of phospho-specific antibodies. It is not suitable for applications requiring aqueous solubility or long-term storage of working solutions.

• HRP Goat Anti-Mouse IgG (H+L) Antibody: Protocols & QC Guide

  2026-04-24

  The HRP Goat Anti-Mouse IgG (H+L) Antibody (SKU: K1221) addresses the need for sensitive and reproducible detection of mouse IgG in immunoassays such as Western blot, ELISA, IHC, and ICC. It is best used where horseradish peroxidase-conjugated secondary antibodies are required for signal amplification, but should not be used outside validated immunoassay formats or with non-mouse primary antibodies.

• Rapamycin (Sirolimus): Protocols and Innovations for mTOR Re

  2026-04-24

  Rapamycin (Sirolimus) is the gold standard for dissecting mTOR signaling, with unmatched potency and specificity for cell proliferation and senescence studies. This article translates new pharmacobiomic findings and proven workflow enhancements into actionable steps for researchers, spotlighting troubleshooting and comparative insights for advanced experimental success.

• Dextromethorphan hydrobromide: Technical Guide for Research

  2026-04-23

  Dextromethorphan hydrobromide is a high-purity NMDA receptor antagonist suited for controlled studies in neuroprotection research, excitotoxicity inhibition, and ion channel modulation. This product is designed exclusively for scientific workflows and should not be applied in diagnostic or clinical contexts, where protocol adherence and correct handling are essential for reproducible results.

• Olaparib (AZD2281): Optimizing DNA Damage Response Assays

  2026-04-23

  Olaparib (AZD2281) empowers precise DNA damage response and tumor radiosensitization workflows, especially in BRCA-deficient cancer research. This article translates recent mechanistic insights and experimental best practices into actionable applications, troubleshooting, and protocol optimization for reproducible results.

• B. pseudomallei BipD Hijacks Host Mitophagy via E3 Ligase Pa

  2026-04-22

  This study demonstrates how Burkholderia pseudomallei utilizes its BipD protein to subvert host mitophagy pathways, facilitating intracellular survival. By elucidating the molecular mechanism involving KLHL9/KLHL13/CUL3 E3 ligase-mediated ubiquitination of IMMT, the research offers key insights into pathogen-driven manipulation of mitochondrial quality control.

• Dextromethorphan hydrobromide: Technical Guidance for Resear

  2026-04-22

  Dextromethorphan hydrobromide is a high-purity NMDA receptor antagonist designed for in vitro and in vivo studies of neuroprotection and excitotoxicity inhibition. It is not suitable for diagnostic or clinical applications, and strict adherence to solubility and storage protocols is required for reproducible results.

• Magnetic Nano-Antibodies Enable In Vivo CAR-T-Mimicry for So

  2026-04-21

  This study introduces a magnetic bispecific nano-antibody (M-BiNanoAb) platform that enables the in vivo generation and magnetic guidance of CAR-T-mimicking cells for solid tumor therapy. The approach bypasses ex vivo genetic modification, enhancing tumor infiltration and antitumor activity, and holds promise for advancing cellular immunotherapies against solid malignancies.

• Wogonin Regulates Macrophage Polarization to Alleviate Osteo

  2026-04-21

  This study reveals how wogonin modulates macrophage polarization and inflammatory signaling via the LSD1-p65 axis, demonstrating chondroprotective effects in a mouse osteoarthritis model. The work advances mechanistic understanding of phytochemical intervention in joint inflammation, with implications for targeted immunomodulatory therapies.

• Advancing Translational Precision: AO/PI Double Staining in

  2026-04-20

  This thought-leadership article explores how the AO/PI Double Staining Kit from APExBIO empowers translational researchers to push the boundaries of cell viability, apoptosis, and necrosis detection—especially in challenging contexts such as rare circulating tumor cell isolation and cancer subtyping. Grounding the discussion in recent mechanistic insights and rigorous benchmarking, we provide actionable guidance for elevating experimental rigor and translational impact.

• SR-202 (PPAR antagonist) for Reliable Immunometabolic Assays

  2026-04-20

  This article guides biomedical researchers in overcoming assay reproducibility and mechanistic clarity challenges using SR-202 (PPAR antagonist), SKU B6929. Through real-world scenarios, we demonstrate how SR-202 optimizes cell-based workflows for insulin resistance, obesity, and inflammation research—grounded in peer-reviewed evidence and practical lab experience.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Precision f

  2026-04-19

  Explore how the JC-1 Mitochondrial Membrane Potential Assay Kit enables unparalleled precision in immunometabolic profiling and apoptosis detection. This in-depth analysis connects mitochondrial membrane potential assays to emerging immunomodulatory strategies in cancer research.

• Thiamet G: Optimizing O-GlcNAcase Inhibition in Bone and Neu

  2026-04-18

  Thiamet G, a potent O-GlcNAcase inhibitor from APExBIO, enables precise control of cellular O-GlcNAcylation in both neurodegenerative and bone metabolism models. This guide delivers actionable workflows, troubleshooting strategies, and data-driven insights for leveraging Thiamet G in diverse experimental contexts.

• AZD0156: ATM Inhibition, Metabolic Synergy, and Protocol Pre

  2026-04-17

  Explore the unique synergy between AZD0156, a potent ATM kinase inhibitor, and metabolic modulation in cancer therapy research. This article delivers protocol-level insights and practical guidance beyond DNA repair, grounded in leading peer-reviewed evidence.

• Targeted Doxycycline Nanoparticles for AAA: Mechanistic Adva

  2026-04-16

  This study introduces a precision nanomedicine platform employing tea polyphenol nanoparticles for targeted doxycycline delivery to abdominal aortic aneurysm (AAA) lesions. By leveraging integrin-targeted surface modification and ROS-responsive release, the approach enhances therapeutic efficacy, mitigates off-target toxicity, and addresses multiple AAA pathologies.

16322 records 1/1089 page Next 12345 下5页 Last page